Bortezomib-Melphalan-Prednisone-Thalidomide Followed by Maintenance With Bortezomib-Thalidomide Compared With Bortezomib-Melphalan-Prednisone for Initial Treatment of Multiple Myeloma: Updated Follow-Up and Improved SurvivalAntonio Palumbo, Michèle Cavo, Giulia Benevolo et al.|Journal of Clinical Oncology|2014Cited by 210
Bortezomib, melphalan, prednisone (VMP) versus melphalan, prednisone, thalidomide (MPT) in elderly newly diagnosed multiple myeloma patients: A retrospective case‐matched studyFortunato Morabito, Massimo Offidani, Sara Galimberti et al.|American Journal of Hematology|2013Cited by 26
Rate of Primary Refractory Disease in B and T-Cell Non-Hodgkin’s Lymphoma: Correlation with Long-Term SurvivalCorrado Tarella, Alessandro Rambaldi, Angela Gueli et al.|PLoS ONE|2014Cited by 26
Life Expectancy in Follicular Lymphoma Is Mainly Determined By Response to First LINE Treatment: A LONG-TERM Survey on 597 PatientsCorrado Tarella, Alessandro Rambaldi, Angela Gueli et al.|Blood|2015Cited by 4